Literature DB >> 17687273

Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine.

V-V Hynninen1, K T Olkkola, L Bertilsson, K Kurkinen, P J Neuvonen, K Laine.   

Abstract

This study investigated the effect of terbinafine and voriconazole on the pharmacokinetics of venlafaxine in healthy volunteers. Plasma concentrations of venlafaxine and O-desmethylvenlafaxine (ODV) were measured after ingestion of 75 mg venlafaxine without pretreatment (control), after terbinafine pretreatment, or after voriconazole pretreatment. During the terbinafine phase, the area under the plasma concentration-time curve (AUC(0-infinity)) of venlafaxine was on average 490% (P<0.001) and that of ODV 57% (P<0.001) of the corresponding control value. Terbinafine decreased the AUC(0-infinity) ratio of ODV over venlafaxine by 82% (P<0.001). Voriconazole slightly increased the sum of AUC(0-infinity) of venlafaxine plus AUC(0-infinity) of ODV (active moiety) by 31% (P<0.001). The most likely mechanism for the interaction between terbinafine and venlafaxine is the inhibition of CYP2D6-mediated O-demethylation of venlafaxine, whereas the minor effects of voriconazole are probably due to the inhibition of CYP3A4-, CYP2C9-, or CYP2C19-mediated metabolism of venlafaxine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17687273     DOI: 10.1038/sj.clpt.6100311

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  11 in total

Review 1.  Clinically significant drug interactions with newer antidepressants.

Authors:  Edoardo Spina; Gianluca Trifirò; Filippo Caraci
Journal:  CNS Drugs       Date:  2012-01-01       Impact factor: 5.749

Review 2.  Age-related changes in antidepressant pharmacokinetics and potential drug-drug interactions: a comparison of evidence-based literature and package insert information.

Authors:  Richard D Boyce; Steven M Handler; Jordan F Karp; Joseph T Hanlon
Journal:  Am J Geriatr Pharmacother       Date:  2012-01-27

3.  Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol.

Authors:  Tuukka Saarikoski; Teijo I Saari; Nora M Hagelberg; Janne T Backman; Pertti J Neuvonen; Mika Scheinin; Klaus T Olkkola; Kari Laine
Journal:  Eur J Clin Pharmacol       Date:  2015-01-06       Impact factor: 2.953

Review 4.  [Terbinafine : Relevant drug interactions and their management].

Authors:  A Dürrbeck; P Nenoff
Journal:  Hautarzt       Date:  2016-09       Impact factor: 0.751

5.  The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.

Authors:  Fen Jiang; Hae-Deun Kim; Han-Sung Na; Seok-Yong Lee; Doo-Won Seo; Jong-Yeol Choi; Ji-Hye Ha; Hee-Jung Shin; Young-Hoon Kim; Myeon-Woo Chung
Journal:  Psychopharmacology (Berl)       Date:  2014-12-17       Impact factor: 4.530

6.  In Vitro and In Vivo Rat Model Assessments of the Effects of Vonoprazan on the Pharmacokinetics of Venlafaxine.

Authors:  Feifei Chen; Hui Jiang; Jia Xu; Shuanghu Wang; Deru Meng; Peiwu Geng; Dapeng Dai; Quan Zhou; Yunfang Zhou
Journal:  Drug Des Devel Ther       Date:  2020-11-10       Impact factor: 4.162

7.  SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study.

Authors:  Akihiro Takano; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2012-10-23       Impact factor: 4.530

8.  Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A.

Authors:  Seongwook Jeong; Phuong D Nguyen; Zeruesenay Desta
Journal:  Antimicrob Agents Chemother       Date:  2008-11-24       Impact factor: 5.191

9.  Update on terbinafine with a focus on dermatophytoses.

Authors:  Jason G Newland; Susan M Abdel-Rahman
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-04-21

10.  Venlafaxine ER Blocks the Norepinephrine Transporter in the Brain of Patients with Major Depressive Disorder: a PET Study Using [18F]FMeNER-D2.

Authors:  Ryosuke Arakawa; Per Stenkrona; Akihiro Takano; Jonas Svensson; Max Andersson; Sangram Nag; Yuko Asami; Yoko Hirano; Christer Halldin; Johan Lundberg
Journal:  Int J Neuropsychopharmacol       Date:  2019-04-01       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.